BRAF and neoplasm: The next clinical trial, titled “Use of Exome Sequence Analysis and Circulating Tumour in Assessing Tumour Heterogeneity in BRAF Mutant Melanoma”, concerns the evolution of BRAF melanoma in response to vemurafenib or dabrafenib.